- Reuters•1 hour ago
Two international medical humanitarian organisations said on Monday they had challenged the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment. Sofosbuvir, sold by the U.S. drugmaker as Sovaldi, is transforming the liver-destroying viral disease by offering an effective cure, but Medecins Sans Frontieres (MSF) and Medecins du Monde (MdM) said its high cost was a serious barrier. The campaigners argue that the patent on the drug is open to challenge because the science behind sofosbuvir is not new.
- TheStreet.com•5 hours ago
Doug Kass shares his thoughts on Alphabet, Allergan and Ford.
- Motley Fool•3 days ago
A look through rose-colored glasses at Gilead Sciences' possible future.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||67.01 x 200|
|Ask||67.63 x 700|
|Day's Range||67.21 - 67.87|
|52 Week Range||65.38 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.79|
|Dividend & Yield||2.08 (3.08%)|
|1y Target Est||N/A|